Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SD Lyfgenia Coverage | Open…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.05.35

    Lyfgenia (lovotibeglogene autotemcel) Coverage for Sickle Cell Disease

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.35 alerts

    Get alerted when Policy 05.05.35 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical necessity review for Lyfgenia in members with sickle cell disease; coverage requires specified clinical, laboratory, genetic, documentation, and prescriber requirements and is limited to one treatment course per lifetime.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyLyfgenia (lovotibeglogene autotemcel) coverage for sickle cell disease
    Policy CodePolicy 05.05.35
    Change TypeNo material change
    Effective DateDec 19, 2025
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with genotype and severe vaso-occlusive event documentation, and ensure prescribing by or consultation with a hematologist or transplant specialist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12-50 yearsInitial approval age range
    ≥4 in 24 monthsSevere vaso-occlusive events
    3 monthsInitial authorization
    1 dose lifetimeTreatment limit
    Hematologist or transplant specialistRequired specialist
    4Billing codes

    Coverage Criteria and Exclusions

    Coverage is excluded when any listed contraindication is present, including advanced liver disease; severe iron overload; clinically significant pulmonary hypertension; baseline estimated GFR less than 70 mL/min/1.73 m²; malignancy other than basal or squamous cell carcinoma of the skin; significant immunodeficiency; an immediate family history of a known familial cancer syndrome; active bacterial, fungal, parasitic, or viral infection, including active or uncontrolled HBV or HCV infection; or a contraindication or hypersensitivity to plerixafor, busulfan, or other medicines required for myeloablative conditioning.

    Additional exclusions include WBC less than 3 × 10⁹/L and/or platelet count less than 100 × 10⁹/L when not related to hypersplenism; severe cerebral vasculopathy, including more than 50% stenosis or occlusion in the circle of Willis; prior gene therapy or allogeneic hematopoietic stem cell transplant; genetic mutations inactivating two or more α-globin genes; and, for members younger than 18 years, availability of a willing matched HLA-identical sibling hematopoietic cell donor.

    Repeat treatment is excluded as investigational for any indication because approval is limited to one treatment course per lifetime. No continuation authorization is available.

    Lyfgenia is considered not medically necessary for members who do not meet the policy’s stated approval criteria.

    Repeat treatment is considered investigational and not medically necessary because the safety and efficacy beyond one dose have not been studied. Coverage is therefore limited to one treatment course per lifetime.

    Initial Approval Criteria

    Continuation and Repeat Therapy

    No repeat treatment

    Continuation or repeat therapy is not covered:

    Repeat treatment

    • Repeat treatment with Lyfgenia for any indication is considered investigational because safety and efficacy beyond one dose have not been studied.
    • Approval is limited to one treatment course per lifetime.One treatment course per lifetime

      No continuation authorization is available.

    Coding and Clinical Thresholds

    Lyfgenia billing codesHCPCS
    J3394Injection, lovotibeglogene autotemcel, per treatment (effective 7/1/2024)
    J3490Unclassified drugs (when specified as [Lyfgenia] (lovotibeglogene autotemcel ))
    J3590Unclassified biologics (when specified as [Lyfgenia] (lovotibeglogene autotemcel ))
    C9399Unclassified drugs or biologics (when specified as [Lyfgenia] (lovotibeglogene autotemcel ))
    Billing CodesHCPCS
    J3394Injection, lovotibeglogene autotemcel, per treatment (effective 7/1/2024)
    J3490Unclassified drugs (when specified as [Lyfgenia] (lovotibeglogene autotemcel ))
    J3590Unclassified biologics (when specified as [Lyfgenia] (lovotibeglogene autotemcel ))
    C9399Unclassified drugs or biologics (when specified as [Lyfgenia] (lovotibeglogene autotemcel ))
    Member age
    Qualifying age range12 through 50 years old
    Minimum age≥ 12 years
    Maximum age≤ 50 years
    Severe vaso-occlusive events
    Required event count4 or more severe vaso-occlusive events
    Lookback periodWithin the previous 24 months
    Care contextEvents must occur despite appropriate supportive care measures

    Authorization, Documentation, and Benefit Requirements

    Prior Authorization

    Prior Authorization and Qualified Specialist Required

    Prior authorization is required for Lyfgenia. The medication must be prescribed by or in consultation with a hematologist or transplant specialist; authorization for sickle cell disease is limited to 3 months for one dose total when all criteria are met.

    • Submit the request for prior authorization review.
    • Ensure the prescribing clinician is a hematologist or transplant specialist, or is consulting with one.
    • Approval is limited to one dose total for the authorized treatment course.
    Step Therapy

    Hydroxyurea Failure or Intolerance Required

    The member must have experienced hydroxyurea (HU) failure or have documented intolerance or inability to tolerate HU before Lyfgenia may be authorized.

    • Document HU failure, intolerance, or inability to tolerate HU in the medical record.

    Therapy Background

    Lyfgenia (lovotibeglogene autotemcel) is indicated for patients at least 12 years of age with sickle cell disease and a history of vaso-occlusive events. The policy addresses patients with genetically confirmed disease and recurrent severe vaso-occlusive events despite appropriate supportive care who are suitable for Lyfgenia and its myeloablative conditioning regimen.

    Policy Definitions

    Severe vaso-occlusive event
    Acute pain eventRequires a visit to a medical facility and administration of pain medications or red blood cell transfusions
    Acute chest syndromeQualifying severe vaso-occlusive event
    Prolonged priapismLasting more than 2 hours and requiring a visit to a medical facility
    Splenic sequestrationQualifying severe vaso-occlusive event
    Hepatic sequestrationQualifying severe vaso-occlusive event
    Covered sickle cell disease genotype
    βs/βs

    Prerequisite Therapy

    StepRequirement
    1Member must have experienced hydroxyurea failure or have intolerance or inability to tolerate hydroxyurea.

    Lifetime Treatment Limit

    Lyfgenia quantity limit
    Treatment limitOne treatment per lifetime
    Applies toLyfgenia approvals
    Repeat treatmentNot available beyond the single lifetime treatment
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyLyfgenia (lovotibeglogene autotemcel) coverage for sickle cell disease
    Policy CodePolicy 05.05.35
    Change TypeNo material change
    Effective DateDec 19, 2025
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with genotype and severe vaso-occlusive event documentation, and ensure prescribing by or consultation with a hematologist or transplant specialist.
    SourceLink
    On This Page
    Coverage Criteria and ExclusionsInitial Approval CriteriaContinuation and Repeat TherapyCoding and Clinical ThresholdsAuthorization, Documentation, and Benefit RequirementsTherapy BackgroundPolicy DefinitionsPrerequisite TherapyLifetime Treatment Limit
    Liver laboratory values
    AST thresholdGreater than 3 times the upper limit of normal
    ALT thresholdGreater than 3 times the upper limit of normal
    Direct bilirubin thresholdGreater than 3 times the upper limit of normal
    Coagulation values
    Prothrombin timeBaseline value greater than 1.5 times the upper limit of normal
    Partial thromboplastin timeBaseline value greater than 1.5 times the upper limit of normal
    Exclusion criterionEither coagulation value exceeding the threshold is disqualifying
    Myocardial iron
    Imaging methodT2*-weighted magnetic resonance imaging
    Measurement assessedMyocardial iron
    Exclusion thresholdLess than 10 msec
    Renal function
    TestBaseline estimated glomerular filtration rate
    Exclusion thresholdLess than 70 mL/min/1.73 m2
    Clinical implicationReduced baseline renal function at this level is an exclusion condition
    Blood counts
    White blood cell countLess than 3 × 10^9/L
    Platelet countLess than 100 × 10^9/L
    Hypersplenism qualificationLow counts are exclusionary when not related to hypersplenism
    Cerebral vasculopathy
    Stenosis thresholdMore than 50%
    Affected anatomyCircle of Willis
    Qualifying findingStenosis or occlusion exceeding the threshold
    Prolonged priapism
    DurationPriapism lasting more than 2 hours
    Required settingRequires a visit to a medical facility
    DefinitionA prolonged priapism episode meeting both the duration and facility-visit requirements is a severe vaso-occlusive event

    Unsupported block type: documentation些 callout

    Denial Risk

    Clinical Eligibility and Exclusion Criteria

    Coverage requires all applicable clinical criteria and is subject to denial when eligibility or exclusion requirements are not met. The member must be 12–50 years old, have a qualifying sickle cell genotype, at least 4 severe vaso-occlusive events in the prior 24 months despite appropriate supportive care, hydroxyurea failure or intolerance, and a negative HIV serology.

    • Qualifying genotypes are βs/βs, βs/β0, or βs/β+; additional genotypes may be considered case by case based on disease severity.
    • The member must not have a willing, matched HLA-identical sibling donor when under age 18.
    • The member must not have advanced liver disease, severe iron overload, clinically significant pulmonary hypertension, or baseline eGFR <70 mL/min/1.73 m².
    • The member must not have prior or current malignancy other than basal or squamous cell skin cancer, a significant immunodeficiency disorder, or an immediate family history of a known familial cancer syndrome.
    • The member must not have an active bacterial, fungal, parasitic, or viral infection, including active or uncontrolled HBV or HCV infection.
    • The member must not have a contraindication to plerixafor, busulfan, or other medicinal products required for myeloablative conditioning.
    • The member must not have WBC <3 × 10⁹/L or platelets <100 × 10⁹/L unrelated to hypersplenism.
    • The member must not have severe cerebral vasculopathy, prior gene therapy, prior allogeneic hematopoietic stem cell transplant, or genetic inactivation of 2 or more α-globin genes.
    Denial Risk

    One-Dose Lifetime Limit

    Repeat treatment is investigational because safety and efficacy beyond one dose have not been studied. Lyfgenia is not medically necessary when the stated criteria are not met, and approval is limited to one treatment course per lifetime.

    • Repeat treatment for any indication is considered investigational.
    • Quantity is limited to one treatment per lifetime.
    • Requests that do not meet the policy criteria may be denied as not medically necessary.
    Billing Rule

    Benefit and Contract Limitations

    Benefit determinations depend on the applicable contract language in effect when services are rendered. Verify the member’s individual benefits before treatment because exclusions, limitations, exceptions, and contract-specific terms may apply; Wellmark determines medical necessity only when the benefit exists and no contract exclusion applies.

    • Verify individual member benefits and applicable contract terms.
    • Coverage may vary by contract, and exclusions, limitations, or exceptions may apply.
    • This medical policy may not apply to the Federal Employee Program; FEP benefits are determined by the Federal Employee Program.
    • Coverage is intended to be consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and published guidelines, provided all approval criteria are met and no exclusion applies.
    Recognized sickle cell disease genotype
    βs/β0Recognized sickle cell disease genotype
    βs/β+Recognized sickle cell disease genotype
    Additional genotypesConsidered case by case based on disease severity